April 2nd 2025
The professor of neurology at Brigham and Women’s Hospital gave clinical insights on the therapeutic potential of targeting compliment as a way to mitigate risk for amyloid-related imaging abnormalities from antiamyloid therapies.
Get direct access to interviews with experts, as well as the latest data and clinical news updates, straight from the conference floor in Dallas, Texas.
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Clinical ShowCase™ in ALS: Addressing Diagnostic Delays, Evolving Therapies, and Multidisciplinary Care
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of FcRN in Neurological Disorders
View More
BURST Expert Illustrations and Commentaries™: Visualizing FcRn as a Therapeutic Target in Neurological Disease
View More
BURST Expert Illustrations and Commentaries™: Visualizing the Implications of FcRN-Targeted Therapies on Generalized Myasthenia Gravis
View More
Clinical Consultations™: Navigating the Evolving Treatment Landscape in Generalized Myasthenia Gravis
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of Subcutaneous Infusion as an Alternate Administration Route for Medical Interventions
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Higher CSF Aß42/Total Tau Ratio Associated With Increased ARIA Risk in Lecanemab
Research suggests that CSF ATI ratios could serve as a biomarker for identifying patients with Alzheimer disease at higher risk of ARIA during lecanemab treatment, aiding in safer patient management.
Eli Lilly Announces Expanded Services to Early Diagnosis and Access Alzheimer Disease Care
Eli Lilly’s expanded LillyDirect platform tackles barriers in Alzheimer disease diagnosis and care, offering telehealth and in-person options through Healthgrades and Synapticure, with a focus on timely access and patient support.
Ubrogepant During Migraine Prodrome Shows Significant Benefits in Patient-Reported Outcomes
March 31st 2025A recent analysis of the PRODROME trial explored the impact of ubrogepant, an FDA-approved acute treatment of migraine with or without aura, on patient-reported outcomes in migraine management.
Mixed Bruxism Episodes More Common in Migraine and Temporomandibular Disorders, Study Finds
March 30th 2025A recent case-control study suggests that although sleep bruxism may not be directly associated with migraine in patients with temporomandibular disorders, mixed bruxism episodes occur more frequently in those with migraine.
WVE-N531 Improves Muscle Health in Latest Phase 2 Trial of Duchenne Muscular Dystrophy
WVE-N531, an investigational exon-skipping therapy, showed promising 48-week results in the FORWARD-53 study, marking the first-ever improvement in muscle health for patients with Duchenne muscular dystrophy, with plans for an NDA filing in 2026.
Breaking the Stigma: Improving Epilepsy Awareness and Care
Emma Macdonald-Laurs, PhD, FRACP, MBChB, a neurologist at the Royal Children’s Hospital in Melbourne, Australia, provided commentary on the progress and challenges the epilepsy community faces amid Purple Day.
Epilepsy Unveiled: Addressing Myths, Treatment Gaps, and New Innovations
Luis Tornes, MD, a neurologist and director of Baptist Health’s Epilepsy Program, provided clinical insights on raising awareness for Purple Day, a global initiative dedicated for patients and families with epilepsy.
Tolebrutinib's potential approval as the first brain-penetrant BTK inhibitor for non-relapsing secondary progressive MS and to slow disability accumulation independent of relapse activity could represent a paradigm shift in treating disability driven by smoldering neuroinflammation.